Mimedx Group Inc logo

MDXG

Mimedx Group Inc

$4.14

Earnings Summary

Revenue
$0.07Mn
Net Profits
$-0.01Mn
Net Profit Margins
-18.68%

Highlights

Revenue:

Mimedx Group Inc’s revenue fell -99.9% since last year same period to $0.07Mn in the Q2 2022. On a quarterly growth basis, Mimedx Group Inc has generated -99.89% fall in its revenue since last 3-months.

Net Profits:

Mimedx Group Inc’s net profit jumped 99.3% since last year same period to $-0.01Mn in the Q2 2022. On a quarterly growth basis, Mimedx Group Inc has generated 99.88% jump in its net profits since last 3-months.

Net Profit Margins:

Mimedx Group Inc’s net profit margin fell -615.88% since last year same period to -18.68% in the Q2 2022. On a quarterly growth basis, Mimedx Group Inc has generated -4.9% fall in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Mimedx Group Inc post its latest quarter earnings

EPS Estimate Current Quarter
-0.06
EPS Estimate Current Year
-0.06

Highlights

EPS Estimate Current Quarter:

Mimedx Group Inc’s earning per share (EPS) estimates for the current quarter stand at -0.06 - a 40% jump from last quarter’s estimates.

EPS Estimate Current Year:

Mimedx Group Inc’s earning per share (EPS) estimates for the current year stand at -0.06.

Key Ratios

Key ratios of the Mimedx Group Inc post its Q2 2022 earnings

Earning Per Share (EPS)
-0.11
Return on Assets (ROA)
-0.06
Return on Equity (ROE)
-0.26
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Mimedx Group Inc’s earning per share (EPS) fell -266.67% since last year same period to -0.11 in the Q2 2022. This indicates that the Mimedx Group Inc has generated -266.67% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Mimedx Group Inc’s return on assets (ROA) stands at -0.06.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Mimedx Group Inc’s return on equity (ROE) stands at -0.26.

Dividend Per Share (DPS):

Mimedx Group Inc declared 0 dividend per share during the earnings announcement for Q2 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-03
-0.1
-0.11
-10%
2022-08-02
-0.06
-0.11
-83.33%

Company Information

MiMedx is an industry leader in utilizing birth tissue as a platform for regenerative medicine, developing and distributing placental tissue allografts with patent-protected, proprietary processes for multiple sectors of healthcare. As a pioneer in placental biologics, the cinoany has both a core business, focused on addressing the needs of patients with acute and chronic non-healing wounds, and a promising late-stage pipeline targeted at decreasing pain and improving function for patients with degenerative musculoskeletal conditions. The company derives its products from human placental tissues and process these tissues using its proprietary processing methods, including the PURION® process. The company employs Current Good Tissue Practices, Current Good Manufacturing Practices, and terminal sterilization to produce its allografts. MiMedx has supplied over two million allografts, through both direct and consignment shipments.

Organisation
Mimedx Group Inc
Employees
735
Industry
Biotechnology